Shares of Revolution Medicines, Inc. (RVMD) are gaining over 7% on Wednesday morning after the company reported progress in RAS cancer therapy.
RVMD is currently trading at $35.48, up $2.49 or 7.55%, on the Nasdaq. The stock opened its trading at $33.98 after closing Wednesday at $32.99. The stock has traded between $15.44 and $37.50 in the past 52-week period.
Revolution Medicines, a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of a peer-reviewed research paper in Cancer Discovery.
The scientific paper details the discovery and preclinical to clinical translation for RMC-6236, an investigational RAS(ON) multi-selective inhibitor, and includes exemplary case studies from the current Phase 1/1b clinical trial demonstrating the initial anti-tumor activity of RMC-6236.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.